FIELD: medicine.
SUBSTANCE: invention relates to medicine, particularly to oncology, and is intended for personalized assignment of neoadjuvant chemotherapy to patients suffering from luminal type B breast cancer. Before assigning the treatment tumour biopsy material is sampled, microchip testing of DNA with determination of markers is performed: gene loci deletion ABCB1-7q21.1, ABCB3-6p21.32, ABCC1-16p13.1, ABCG2-4q22, MVP-16p11.2; deletion 18p11.21; deletion 11q22.1-23.3; amplification 1q24.1-43. If no above markers have been found in the tumour tissue, surgical treatment is started in the volume of radical mastectomy or conservative surgery. If at least 1 of the above markers is detected, neoadjuvant chemotherapy is performed prior to surgical treatment.
EFFECT: invention increases the efficiency of neoadjuvant chemotherapy, adequate treatment planning in adjuvant mode and improvement of long-term results.
1 cl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF COMBINATION TREATMENT OF NON-SMALL CELL LUNG CANCER STAGE 1B-111 WITH CUSTOMIZATION OF ADJUVANT CHEMOTHERAPY | 2015 |
|
RU2593342C1 |
| METHOD FOR COMBINED TREATMENT OF NON-SMALL CELL LUNG CANCER IB-III STAGE USING PERSONALIZED PERIOPERATIVE CHEMOTHERAPY | 2019 |
|
RU2706718C1 |
| METHOD OF PERSONALIZED COMBINED TREATMENT OF NON-CELL LUNG CANCER 1B-111 STAGE ON THE BASIS OF ESTIMATION OF THE LEVELS OF EXPRESSION OF MONORESISTENCE GENES | 2017 |
|
RU2665133C1 |
| METHOD FOR PERSONALIZED COMBINED TREATMENT OF PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER STAGE II-III | 2022 |
|
RU2784958C1 |
| METHOD FOR PREDICTION OF COMPLETE MORPHOLOGICAL REGRESSIONS IN PATIENTS SUFFERING TRIPLE-NEGATIVE RESECTABLE BREAST CANCER | 2014 |
|
RU2560707C1 |
| METHOD FOR PREDICTION OF FULL REGRESSION PROBABILITY DURING NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH THREE-TIMES NEGATIVE MOLECULAR-GENETIC SUBTYPE OF BREAST CANCER | 2016 |
|
RU2623118C1 |
| METHOD FOR PREDICTION OF DEGREE OF FULL REGRESSION PROBABILITY DURING NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH LUMINAL MOLECULAR-GENETIC SUBTYPE OF BREAST CANCER | 2016 |
|
RU2632112C1 |
| METHOD OF FORECASTING PERSONSIVE SURVIVABILITY IN PATIENTS WITH BREAST CANCER | 2016 |
|
RU2623869C1 |
| METHOD FOR PREDICTING FIVE-YEAR NONMETASTATIC SURVIVAL IN BREAST CANCER PATIENTS BASED ON THE EXPRESSION OF THE YKL-39 AND CCL18 PROTEIN GENES | 2017 |
|
RU2659676C1 |
| METHOD FOR DETERMINATION OF RISK OF BREAST ONCOLOGICAL DISEASES RECURRENCE | 2015 |
|
RU2626603C2 |
